Skip to content

Services
Choose the pressure point closest to the decision your team needs to make.
Submission & CMCPathway, dossier, evidence, control strategy, or Module 3 readiness.Quality & Data IntegrityGMP remediation, audit trails, completeness, governance, or controls.Inspection & EnforcementReadiness, response, remediation, verification, or sustainment.AI-Enabled CMCStructured CMC data, regulatory modernization, digital governance, and decision support.
Explore all services Start with your situation
Who We Help
Insights
Intelligence hubs
Insights HubThe starting point for XGene analysis and intelligence.Regulatory Intelligence CenterSearch governed regulatory findings, guidance, and related evidence.CMC IntelligenceEvidence connected across the product lifecycle.
Analysis & resources
Articles & Case StudiesSenior-authored analysis with applied regulatory context.Regulatory RecordsBrowse the governed primary-source record archive.Resource CenterStructured reference tools and practical resources.
Media & practical answers
PodcastExpert conversations connecting evidence, judgment, and action.VideoVisual briefings that make regulated systems easier to understand.FAQsConcise answers that orient a regulatory, CMC, quality, or inspection question.
Featured AnalysisThe ICH Q11 Three-Part Justification — What FDA and EMA Require for Starting Material Designation and Where Programs Fall ShortXGene analysis · Aug 22, 2026Read Article →
About
- Methodology
Contact
Book a Call
Discuss a Project

Services
Choose the pressure point closest to the decision your team needs to make.
Submission & CMCPathway, dossier, evidence, control strategy, or Module 3 readiness.Quality & Data IntegrityGMP remediation, audit trails, completeness, governance, or controls.Inspection & EnforcementReadiness, response, remediation, verification, or sustainment.AI-Enabled CMCStructured CMC data, regulatory modernization, digital governance, and decision support.
Explore all services Start with your situation
Who We Help
Insights
Intelligence hubs
Insights HubThe starting point for XGene analysis and intelligence.Regulatory Intelligence CenterSearch governed regulatory findings, guidance, and related evidence.CMC IntelligenceEvidence connected across the product lifecycle.
Analysis & resources
Articles & Case StudiesSenior-authored analysis with applied regulatory context.Regulatory RecordsBrowse the governed primary-source record archive.Resource CenterStructured reference tools and practical resources.
Media & practical answers
PodcastExpert conversations connecting evidence, judgment, and action.VideoVisual briefings that make regulated systems easier to understand.FAQsConcise answers that orient a regulatory, CMC, quality, or inspection question.
Featured AnalysisThe ICH Q11 Three-Part Justification — What FDA and EMA Require for Starting Material Designation and Where Programs Fall ShortXGene analysis · Aug 22, 2026Read Article →
About
- Methodology
Contact
Book a Call
Discuss a Project

Regulatory evidence

Primary-source signals organized for decisions.

Browse governed regulatory records and connect source evidence to technical context, XGene analysis, and practical pathways.

Regulatory evidenceDecision

01Source

02Agency

03Context

04Action

Warning Letters

Pharmathen International Warning Letter: Aseptic Processing Failures and the CMC Pattern Every Sterile Products Quality Director Must Recognize XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

FDA 483 Trend Analysis — March-May 2026: What Inspectors Are Finding at Compounding Pharmacy and Outsourcing Facility Aseptic Programs Right Now XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

Zydus Pharmaceuticals Class II Recall — Mirabegron Extended-Release Tablets: The Manufacturing Quality Signal Behind the Notice and What It Reveals About Nitrosamine Control Strategy XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

Zhejiang Gaorong Cosmetic Co., Ltd. Added to Import Alert 66-40: The CGMP Pattern Behind the Detention and What Every Quality Director Managing Cross-Category Drug, Biologic, and Supplement Supply Chains Must Know XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

Consent Decrees

Inside Genzyme’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will Accept XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

FDA Guidance / Regulatory Developments

FDA’s New Container Closure and Device Constituent Part Draft Guidance for Biosimilars — Why the Comparative Task Analysis Framework Deserves a Formal XGene-Style Comment XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

International Enforcement

International GMP Enforcement — Q3 2026: Pattern Analysis Across 14 Actions and What the Trend Signals for Global Pharmaceutical Quality XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

Warning Letters

Pharmathen International Warning Letter: Aseptic Processing Failures and the CMC Pattern Every Sterile Products Quality Director Must Recognize XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

FDA 483 Trend Analysis — March-May 2026: What Inspectors Are Finding at Compounding Pharmacy and Outsourcing Facility Aseptic Programs Right Now XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

Zydus Pharmaceuticals Class II Recall — Mirabegron Extended-Release Tablets: The Manufacturing Quality Signal Behind the Notice and What It Reveals About Nitrosamine Control Strategy XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

Zhejiang Gaorong Cosmetic Co., Ltd. Added to Import Alert 66-40: The CGMP Pattern Behind the Detention and What Every Quality Director Managing Cross-Category Drug, Biologic, and Supplement Supply Chains Must Know XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

Consent Decrees

Inside Genzyme’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will Accept XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

FDA Guidance / Regulatory Developments

FDA’s New Container Closure and Device Constituent Part Draft Guidance for Biosimilars — Why the Comparative Task Analysis Framework Deserves a Formal XGene-Style Comment XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

International Enforcement

International GMP Enforcement — Q3 2026: Pattern Analysis Across 14 Actions and What the Trend Signals for Global Pharmaceutical Quality XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

Public library

Browse the published XGene collection.

Insights Hub →

Regulatory Record Gopaldas Visram & Co., Ltd. Warning Letter: IR Spectroscopy and Component Testing Failures Every QC Director Must Recognize On June 2, 2026, FDA issued Warning Letter 320-26-86 to Gopaldas Visram & Co., Ltd., an OTC drug product manufacturer located in Navi Mumbai, Maharashtra, India, citing failures… Aug 22, 2026 →

Regulatory Record Laboratorios Dr. Collado Warning Letter: Laboratory Controls and the CMC Pattern Every OTC Drug Quality Director Must Recognize On June 2, 2026, FDA issued Warning Letter 320-26-87 to Laboratorios Dr. Collado S.A., an over-the-counter drug manufacturer at Parque Industrial Duarte Km 22 1/2, Autopista Duarte, Santo… Aug 22, 2026 →

Previous 1 … 3 4 5

XGene Intelligence Discovery

Search this collection and connected XGene intelligence.

Stay within this content family or broaden into related evidence, analysis, resources, and services.

Search Content Domain CMC Authority Action Modality Region Sort

Loading governed XGene intelligence…

Regulatory and quality consulting for pharmaceutical, biotechnology, and medical-device organizations.

Services

Regulatory Strategy CMC & Module 3 Quality & Data Integrity Inspection Readiness AI-Enabled CMC

Insights

Insights Hub Regulatory Intelligence Center Articles & Case Studies CMC Intelligence Resource Center Podcast Video

Company

About XGene Who We Help Contact Book a Call Discuss a Project

© 2026 XGene LLC · XGene Consulting Services · Troy, Michigan Privacy & Cookies · Terms · Disclaimer · Accessibility

XGene Navigator

Find the right evidence, insight, or service.

Search XGene

Services Regulatory Evidence Analysis FAQs Resources Video Podcast

Start typing to search across XGene's public knowledge base.

Saved for later

My XGene Library

Save public XGene articles, records, resources, and services on this device for quick return.

Saved items

Recently viewed